Armata Pharmaceuticals, Inc. (ARMP): debt financing — Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan

Armata Pharmaceuticals, Inc.

Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.
Revenue of $0.8M (grant) up from $0.5M; R&D spend $6.1M vs $5.4M; cash $4.8M down from $8.7M.
Entered $25M secured term loan with Innoviva at 14% interest, maturing Jan 11, 2029.
AP-SA02 Phase 3 superiority study in S. aureus bacteremia expected to start H2 2026; FDA granted QIDP and Fast Track.
Appointed Daniel Gilmer to Board; ~36.7M shares outstanding as of May 8, 2026.

item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 1.0

Armata Pharmaceuticals, Inc. incurred term loan of $25 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.

Instrument: term loan
Principal: $25 million
Counterparty: Innoviva Strategic Opportunities LLC
Rate: 14.0% per annum
Maturity: January 11, 2029
Event: incurrence

Exact text from the filing

On May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13, 2026, the Company announced its financial results for the three months ended March 31, 2026

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Armata Pharmaceuticals, Inc. entered into May 2026 Credit Agreement with Innoviva Strategic Opportunities LLC (Innoviva) valued at $25 million (effective 2026-05-12).

Action: entry
Agreement: credit facility
Counterparty: Innoviva Strategic Opportunities LLC (Innoviva)
Value: $25 million
Effective: 2026-05-12

Exact text from the filing

on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million

View on SEC.gov

73 debt financings filed in the last 30 days. Browse all debt financings →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-060299

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.